Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Clinical trial NCT07150403 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07150403
Sponsor: Federation Francophone de Cancerologie Digestive
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Colorectal Carcinoma (mCRC)

Start date: 2025-12-31
Primary completion: 2028-02-28
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.